MX345954B - Inhibicion de tirosina cinasa esplenica mediada por arni relacionada con trastornos inflamatorios. - Google Patents

Inhibicion de tirosina cinasa esplenica mediada por arni relacionada con trastornos inflamatorios.

Info

Publication number
MX345954B
MX345954B MX2013005786A MX2013005786A MX345954B MX 345954 B MX345954 B MX 345954B MX 2013005786 A MX2013005786 A MX 2013005786A MX 2013005786 A MX2013005786 A MX 2013005786A MX 345954 B MX345954 B MX 345954B
Authority
MX
Mexico
Prior art keywords
related inflammatory
tyrosine kinase
rnai
spleen tyrosine
inflammatory conditions
Prior art date
Application number
MX2013005786A
Other languages
English (en)
Inventor
M Yanni John
A Gamache Daniel
E Chatterton Jon
T Miller Steven
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of MX345954B publication Critical patent/MX345954B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a la interferencia de un ARN para la inhibición de la expresión del ARNm de tirosina cinasa esplénica (Syk), en particular, para tratar pacientes que tienen una condición inflamatoria relacionada con Syk o en riesgo de desarrollar una condición inflamatoria relacionada con Syk tal como conjuntivitis alérgica, inflamación ocular, dermatitis, rinitis, asma, alergia o enfermedad de mastocitos.
MX2013005786A 2006-04-13 2007-04-13 Inhibicion de tirosina cinasa esplenica mediada por arni relacionada con trastornos inflamatorios. MX345954B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79184706P 2006-04-13 2006-04-13
PCT/US2007/066619 WO2007121347A2 (en) 2006-04-13 2007-04-13 Rnai-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions

Publications (1)

Publication Number Publication Date
MX345954B true MX345954B (es) 2017-02-16

Family

ID=38610402

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2008013068A MX2008013068A (es) 2006-04-13 2007-04-13 Inhibicion de tirosina cinasa esplenda mediada por arni relacionada con trastornos inflamatorios.
MX2013005786A MX345954B (es) 2006-04-13 2007-04-13 Inhibicion de tirosina cinasa esplenica mediada por arni relacionada con trastornos inflamatorios.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2008013068A MX2008013068A (es) 2006-04-13 2007-04-13 Inhibicion de tirosina cinasa esplenda mediada por arni relacionada con trastornos inflamatorios.

Country Status (13)

Country Link
US (4) US8048863B2 (es)
EP (3) EP2004240A4 (es)
JP (1) JP2009533475A (es)
KR (1) KR20080110900A (es)
CN (2) CN101972483A (es)
AR (1) AR060448A1 (es)
AU (2) AU2007238027B2 (es)
BR (1) BRPI0709506A2 (es)
CA (1) CA2649138C (es)
MX (2) MX2008013068A (es)
TW (2) TW200808360A (es)
WO (1) WO2007121347A2 (es)
ZA (1) ZA200808744B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090087413A1 (en) * 2007-10-01 2009-04-02 Alcon Research, Ltd. Self-complementary aav-mediated delivery of interfering rna molecules to treat or prevent ocular disorders
EP2306993B1 (en) * 2008-05-26 2014-03-12 Universität Zürich Protamine/rna nanoparticles for immunostimulation
WO2010074992A2 (en) * 2008-12-22 2010-07-01 Otonomy, Inc. Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
EP2865758A1 (en) * 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the ORAI1 gene
CN104805085A (zh) * 2014-01-29 2015-07-29 江苏命码生物科技有限公司 串联表达的siRNA及其在治疗慢性淋巴细胞白血病中的应用
WO2016108264A1 (ja) * 2014-12-29 2016-07-07 株式会社ボナック 核酸分子を安定に含有する組成物
WO2016192741A1 (en) 2015-05-29 2016-12-08 Ablacon Inc. Elongated medical device suitable for intravascular insertion, optical force sensing assembly for an elongated medical device and method of making a medical optical force sensing assembly
RU2714257C2 (ru) * 2015-10-30 2020-02-13 Бонак Корпорейшн КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ В СТАБИЛЬНОМ СОСТОЯНИИ ОДНОЦЕПОЧЕЧНУЮ МОЛЕКУЛУ НУКЛЕИНОВОЙ КИСЛОТЫ, КОТОРАЯ ПОДАВЛЯЕТ ЭКСПРЕССИЮ ГЕНА TGF-β1
BR102018001541B1 (pt) 2018-01-24 2021-05-11 Universidade Federal Do Rio Grande Do Sul composição farmacêutica nanométrica na forma de lipossomas ou nanoemulsão que contém sequências específicas de rna de interferência

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360720A (en) 1993-10-08 1994-11-01 Alcon Laboratories, Inc. Method of preparing human conjunctival mast cells for mast cell stabilization assays
US5545626A (en) * 1994-01-19 1996-08-13 The Trustees Of Columbia University In The City Of New York Method of treating glaucoma with oligonucleotides
AU723595B2 (en) * 1995-06-07 2000-08-31 University Of Pennsylvania Methods of inhibiting phagocytosis
CA2526831C (en) * 2001-05-18 2012-07-31 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)
US20050227935A1 (en) * 2001-05-18 2005-10-13 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA)
ES2447566T3 (es) * 2002-10-01 2014-03-12 Epigenomics Ag Uso de ácidos nucleicos de PITX2 para mejorar el tratamiento de trastornos proliferativos de células mamarias
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
JP2006507841A (ja) * 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
CN101914532A (zh) * 2002-11-22 2010-12-15 生物智囊团株式会社 Rna干扰的目标碱基序列的搜索方法
AU2003224132A1 (en) * 2003-04-24 2004-11-19 Galapagos Genomics N.V. Effective sirna knock-down constructs
US7173015B2 (en) * 2003-07-03 2007-02-06 The Trustees Of The University Of Pennsylvania Inhibition of Syk kinase expression
WO2005049838A2 (en) * 2003-11-14 2005-06-02 Yale University Syk-targeted nucleic acid interference
GB0404209D0 (en) 2004-02-25 2004-03-31 Uws Ventures Ltd Materials and methods for treatment of allergic disease
JP2007527240A (ja) * 2004-03-01 2007-09-27 マサチューセッツ インスティテュート オブ テクノロジー アレルギー性鼻炎および喘息のためのＲＮＡｉベースの治療
EP1904649A2 (en) 2005-07-18 2008-04-02 Epigenomics AG Compositions and methods for cancer diagnostics comprising pan-cancer markers
CA2633035C (en) * 2005-12-15 2016-05-10 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
WO2009020847A2 (en) 2007-08-03 2009-02-12 Alcon Research, Ltd. Rnai-related inhibition of tnfa signaling pathway for treatment of ocular angiogenesis

Also Published As

Publication number Publication date
MX2008013068A (es) 2008-12-16
EP2004240A2 (en) 2008-12-24
AR060448A1 (es) 2008-06-18
TW200808360A (en) 2008-02-16
EP3156486A2 (en) 2017-04-19
CN101972483A (zh) 2011-02-16
US8048863B2 (en) 2011-11-01
AU2007238027A1 (en) 2007-10-25
KR20080110900A (ko) 2008-12-19
TW201336514A (zh) 2013-09-16
US20110288157A1 (en) 2011-11-24
CA2649138C (en) 2018-04-03
US20140357695A1 (en) 2014-12-04
ZA200808744B (en) 2009-12-30
CA2649138A1 (en) 2007-10-25
US8865671B2 (en) 2014-10-21
BRPI0709506A2 (pt) 2011-07-19
WO2007121347A2 (en) 2007-10-25
EP2004240A4 (en) 2010-12-15
US20160257963A1 (en) 2016-09-08
WO2007121347A3 (en) 2008-12-04
AU2007238027B2 (en) 2013-08-15
EP2662446A3 (en) 2014-04-02
AU2013207601B2 (en) 2016-11-17
CN101443020A (zh) 2009-05-27
US20090324507A1 (en) 2009-12-31
EP2662446A2 (en) 2013-11-13
EP3156486A3 (en) 2017-07-12
JP2009533475A (ja) 2009-09-17
US9371529B2 (en) 2016-06-21

Similar Documents

Publication Publication Date Title
MX345954B (es) Inhibicion de tirosina cinasa esplenica mediada por arni relacionada con trastornos inflamatorios.
ATE510841T1 (de) Thiazoliopyrimidine und ihre verwendung als hemmer der phosphatidylinositol-3 kinase
WO2007076367A3 (en) Rnai-mediated inhibition of rho kinase for treatment of ocular hypertension / glaucoma
UY30361A1 (es) Inhibición mediada por el arni de las afecciones vinculadas al factor a (alfa) de necrosis tumoral
MX2009001896A (es) Inhibicion medida por arn-i de gremlin para el tratamiento de condiciones relacionadas con iop.
MY159230A (en) P38 map kinase inhibitors
WO2009061924A3 (en) Aldh-2 inhibitors in the treatment of psychiatric disorders
WO2007092095A3 (en) [4-(benzo [b] thi0phen-2-yl) pyrimidin-2yl] -amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases.
WO2008060767A3 (en) Macrocyclic benzofused pyrimidine derivatives
SG179410A1 (en) Therapeutic uses of inhibitors of rtp801
ZA200704932B (en) Rnai inhibition of CTGF for treatment of ocular disorders
WO2009006389A3 (en) Pyrimidine derivatives useful as raf kinase inhibitors
WO2007146824A3 (en) Quinoline compounds and methods of use
NO20070933L (no) Indazoler anvendbare i behandling av kardiovaskulaere sykdommer
WO2009111278A3 (en) Raf inhibitor compounds and methods of use thereof
WO2008005457A3 (en) Pyridinonyl pdk1 inhibitors
WO2008067121A3 (en) Methods of treating cognitive impairment and dementia
WO2006125101A3 (en) Raf inhibitor compounds and methods of use thereof
MX338504B (es) Combinaciones de compuestos inhibidores de fosfoinosituro 3-cinasa y agentes quimioterapeuticos, y metodos de uso.
WO2010068794A3 (en) Hif inhibitors and use thereof
ZA200703990B (en) Inhibitors of Jun N-terminal kinases for treating glaucomatous retinopathy and ocular diseases
MX2009005725A (es) Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13.
AU2013207601A1 (en) RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
EP2073843A4 (en) METHOD FOR DIAGNOSING, TREATING OR PREVENTING PLASMA CELL DISEASES
DE602006007323D1 (de) VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN